Search research articles
Contact Us
Filters
Showing results (131-140 of 183) with videos related to
Page
of 19
Sort By:
The New England Journal of Medicine
|
September 30, 2020
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S Herbst, Giuseppe Giaccone, Filippo de Marinis, et al.
Lancet (London, England)
|
September 23, 2020
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A Mittendorf, Hong Zhang, Carlos H Barrios, et al.
Therapeutic Advances in Medical Oncology
|
October 6, 2025
Factors associated with accepting chemotherapy despite the risk of fertility loss in Latin American breast cancer patients-LACOG 0414 study
Gustavo Werutsky, Cynthia Villarreal-Garza, Henry L Gomez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 20, 2019
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC
Pere Gascón, Rajnish Nagarkar, Martin Šmakal, et al.
Ecancermedicalscience
|
August 3, 2023
Clinical validation and diagnostic accuracy of <sup>99m</sup>Tc-EDDA/HYNIC-TOC compared to <sup>111</sup>In-DTPA-octreotide in patients with neuroendocrine tumours: the LACOG 0214 study
Cristina M Moriguchi-Jeckel, Rafael R Madke, Graciane Radaelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2013
Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2
Mauro Zukin, Carlos H Barrios, Jose Rodrigues Pereira, et al.
Nature Medicine
|
June 4, 2025
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial
Elizabeth A Mittendorf, Zoe June Assaf, Nadia Harbeck, et al.
Journal of the National Cancer Institute
|
June 8, 2018
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini, Christine Campbell, José Bines, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
R J Motzer, B Escudier, M Burotto, et al.
JCO Global Oncology
|
January 11, 2024
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline
Sana Al Sukhun, Sarah Temin, Carlos H Barrios, et al.
Page
of 19
Search research articles
Search
Showing results (131-140 of 183) with videos related to
Sort By:
Page
of 19
The New England Journal of Medicine
|
September 30, 2020
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S Herbst, Giuseppe Giaccone, Filippo de Marinis, et al.
Lancet (London, England)
|
September 23, 2020
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A Mittendorf, Hong Zhang, Carlos H Barrios, et al.
Therapeutic Advances in Medical Oncology
|
October 6, 2025
Factors associated with accepting chemotherapy despite the risk of fertility loss in Latin American breast cancer patients-LACOG 0414 study
Gustavo Werutsky, Cynthia Villarreal-Garza, Henry L Gomez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 20, 2019
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC
Pere Gascón, Rajnish Nagarkar, Martin Šmakal, et al.
Ecancermedicalscience
|
August 3, 2023
Clinical validation and diagnostic accuracy of <sup>99m</sup>Tc-EDDA/HYNIC-TOC compared to <sup>111</sup>In-DTPA-octreotide in patients with neuroendocrine tumours: the LACOG 0214 study
Cristina M Moriguchi-Jeckel, Rafael R Madke, Graciane Radaelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2013
Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2
Mauro Zukin, Carlos H Barrios, Jose Rodrigues Pereira, et al.
Nature Medicine
|
June 4, 2025
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial
Elizabeth A Mittendorf, Zoe June Assaf, Nadia Harbeck, et al.
Journal of the National Cancer Institute
|
June 8, 2018
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini, Christine Campbell, José Bines, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
R J Motzer, B Escudier, M Burotto, et al.
JCO Global Oncology
|
January 11, 2024
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline
Sana Al Sukhun, Sarah Temin, Carlos H Barrios, et al.
Page
of 19